Company & Sponsor Intelligence

Georgetown University

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting1

Completed3

Countries1

Therapeutic footprint

alzheimersdepressionparkinsons

Indexed studies

NCT02947893Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE2

NCT00348036Group Intervention for Interpersonal Trauma
depression · United StatesNA

NCT03702907DC Longitudinal Study on Aging and Specimen Bank
alzheimers · United StatesRECRUITING

NCT02281474Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
parkinsons · United StatesPHASE1

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →